<DOC>
	<DOCNO>NCT01582997</DOCNO>
	<brief_summary>BRF116056 first clinical experience GSK2118436 , BRAF inhibitor , Japan . This study design assess safety , tolerability , single repeat dose PK profile preliminary efficacy GSK2118436 Japanese subject BRAF V600 mutation positive solid tumor use continuous daily dose schedule .</brief_summary>
	<brief_title>A Phase I Study Investigate Safety , Tolerability Pharmacokinetic Profile GSK2118436 Japanese Subjects With BRAF Mutation Positive Solid Tumors</brief_title>
	<detailed_description>BRF116056 first clinical experience GSK2118436 , BRAF inhibitor , Japan . This study design assess safety , tolerability , single repeat dose PK profile preliminary efficacy GSK2118436 Japanese subject BRAF V600 mutation positive solid tumor use continuous daily dose schedule . Dose escalation GSK2118436 perform accord standard 3+3 dose-escalation design . GSK2118436 give twice day . However , characterize PK GSK2118436 metabolites single-dose administration , GSK2118436 NOT administrate week first administration . GSK2118436 continuous dose start 168-hour PK sample obtain . Subjects may receive study treatment disease progression , death unacceptable adverse event .</detailed_description>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis solid tumor responsive standard therapy approve curative therapy . Subjects must BRAF V600E K mutant positive tumor . Women reproductive potential must willing practice acceptable method birth control study 4 week last dose study medication . Men reproductive potential must willing practice acceptable method birth control study 16 week last dose study medication . Must adequate organ function . Must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . Currently receive cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy surgery ) . Use investigational anticancer drug within 28 day precede first dose GSK2118436 . A history malignancy . Subjects diseasefree 5 year subject history complete resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . History Human Immunodeficiency Virus ( HIV ) infection . Certain cardiac abnormality . Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>BRAF</keyword>
	<keyword>Advance solid tumor</keyword>
</DOC>